“DESTINY-Breast11 results support T-DXd [plus] THP as a more effective and less toxic neoadjuvant treatment compared with ddAC-THP, and it may become the preferred regimen for patients with high-risk, ...
Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...
MedPage Today on MSN
'Remarkable' Survival Outcomes in Cisplatin-Ineligible Bladder Cancer
Event-free survival (EFS) improved by 60% and overall survival (OS) by 50% with the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) versus upfront radical ...
Imfinzi plus FLOT chemotherapy significantly improves overall survival in resectable G/GEJ adenocarcinoma compared to placebo ...
The Nifty 50 index is expected to face resistance at the 25,900–26,000 zone on the Muhurat Trading day, while support is ...
The combination of Merck’s Keytruda and Pfizer and Astellas’ Padcev reduced patients' risk of death by a whopping 50% when used before and after bladder removal surgery in those with MIBC who are not ...
A New Era in the Treatment of Muscle Invasive Bladder Cancer. Discussant of LBA2 - Perioperative (Periop) Enfortumab Vedotin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback